

Andreas D Hartkopf

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7768311/publications.pdf>

Version: 2024-02-01

92
papers

1,977
citations

331670

21
h-index

289244

40
g-index

124
all docs

124
docs citations

124
times ranked

2721
citing authors

#	ARTICLE	IF	CITATIONS
1	Early dissemination seeds metastasis in breast cancer. <i>Nature</i> , 2016, 540, 552-558.	27.8	550
2	Prognostic relevance of disseminated tumour cells from the bone marrow of early stage breast cancer patients â€” Results from a large single-centre analysis. <i>European Journal of Cancer</i> , 2014, 50, 2550-2559.	2.8	60
3	Changing levels of circulating tumor cells in monitoring chemotherapy response in patients with metastatic breast cancer. <i>Anticancer Research</i> , 2011, 31, 979-84.	1.1	59
4	Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry. <i>Breast</i> , 2018, 37, 154-160.	2.2	56
5	Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors â€” Data from the German PRAEGNANT breast cancer registry. <i>Breast</i> , 2018, 37, 42-51.	2.2	54
6	Reliability of an e-PRO Tool of EORTC QLQ-C30 for Measurement of Health-Related Quality of Life in Patients With Breast Cancer: Prospective Randomized Trial. <i>Journal of Medical Internet Research</i> , 2017, 19, e322.	4.3	48
7	Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 143-151.	2.5	45
8	Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry. <i>Cancers</i> , 2019, 11, 10.	3.7	43
9	Use of complementary and integrative medicine among German breast cancer patients: predictors and implications for patient care within the PRAEGNANT study network. <i>Archives of Gynecology and Obstetrics</i> , 2017, 295, 1239-1245.	1.7	42
10	Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 319-328.	2.5	40
11	Mutations in <i>BRCA1/2</i> and Other Panel Genes in Patients With Metastatic Breast Cancer â€” Association With Patient and Disease Characteristics and Effect on Prognosis. <i>Journal of Clinical Oncology</i> , 2021, 39, 1619-1630.	1.6	39
12	Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status. <i>European Journal of Cancer</i> , 2021, 155, 1-12.	2.8	39
13	Electronic-Based Patient-Reported Outcomes: Willingness, Needs, and Barriers in Adjuvant and Metastatic Breast Cancer Patients. <i>JMIR Cancer</i> , 2017, 3, e11.	2.4	38
14	Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer â€” Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. <i>Breast</i> , 2020, 54, 88-95.	2.2	34
15	An Electronic Patient-Reported Outcome Tool for the FACT-B (Functional Assessment of Cancer) Tj ETQq1 1 0.784314 rgBT /Overlock Breast Cancer: Reliability Study. <i>Journal of Medical Internet Research</i> , 2019, 21, e10004.	4.3	29
16	The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 93-104.	2.5	28
17	Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 59-65.	2.5	27
18	The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer. <i>Scientific Reports</i> , 2019, 9, 2318.	3.3	27

#	ARTICLE	IF	CITATIONS
19	Oncolytic virotherapy of gynecologic malignancies. <i>Gynecologic Oncology</i> , 2011, 120, 302-310.	1.4	26
20	Update Breast Cancer 2019 Part 3 â€“ Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 470-482.	1.8	26
21	Dormancy in breast cancer. <i>Breast Cancer: Targets and Therapy</i> , 2012, 4, 183.	1.8	25
22	Implementation and Feasibility of Electronic Patient-Reported Outcome (ePRO) Data Entry in the PRAEGNANT Real-Time Advanced and Metastatic Breast Cancer Registry. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017, 77, 870-878.	1.8	24
23	Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis. <i>European Journal of Cancer</i> , 2021, 154, 128-137.	2.8	24
24	Impact of apoptotic circulating tumor cells (aCTC) in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 277-290.	2.5	23
25	Update Breast Cancer 2018 (Part 2) â€“ Advanced Breast Cancer, Quality of Life and Prevention. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 246-259.	1.8	23
26	Detection of ESR1 Mutations in Single Circulating Tumor Cells on Estrogen Deprivation Therapy but Not in Primary Tumors from Metastatic Luminal Breast Cancer Patients. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 111-121.	2.8	22
27	Update Breast Cancer 2019 Part 2 â€“ Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 268-280.	1.8	21
28	Simultaneous Detection of Disseminated and Circulating Tumor Cells in Primary Breast Cancer Patients. <i>Cancer Research and Treatment</i> , 2016, 48, 115-124.	3.0	20
29	Update Breast Cancer 2018 (Part 1) â€“ Primary Breast Cancer and Biomarkers. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 237-245.	1.8	20
30	Update Breast Cancer 2017 â€“ Implementation of Novel Therapies. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017, 77, 1281-1290.	1.8	19
31	Cut-Off Analysis of CTC Change under Systemic Therapy for Defining Early Therapy Response in Metastatic Breast Cancer. <i>Cancers</i> , 2020, 12, 1055.	3.7	19
32	HER2-Positive DTCs/CTCs in Breast Cancer. <i>Recent Results in Cancer Research</i> , 2012, 195, 203-215.	1.8	19
33	Update Breast Cancer 2019 Part 4 â€“ Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 1079-1089.	1.8	18
34	Update Breast Cancer 2019 Part 1 â€“ Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 256-267.	1.8	17
35	Pooled analysis of two randomized phase III trials (PlanB/SuccessC) comparing six cycles of docetaxel and cyclophosphamide to sequential anthracycline taxane chemotherapy in patients with intermediate and high risk HER2-negative early breast cancer (n=5,923).. <i>Journal of Clinical Oncology</i> , 2018, 36, 522-522.	1.6	17
36	Tumor cell dissemination to the bone marrow and blood is associated with poor outcome in patients with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 345-351.	2.5	16

#	ARTICLE	IF	CITATIONS
37	Update Breast Cancer 2019 Part 5 â€œ Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2019, 79, 1090-1099.	1.8	16
38	Update Breast Cancer 2020 Part 1 â€œ Early Breast Cancer: Consolidation of Knowledge About Known Therapies. Geburtshilfe Und Frauenheilkunde, 2020, 80, 277-287.	1.8	16
39	Relationship Between Hematogenous Tumor Cell Dissemination and Cellular Immunity in DCIS Patients. Anticancer Research, 2016, 36, 2345-51.	1.1	16
40	Bone marrow versus sentinel lymph node involvement in breast cancer: a comparison of early hematogenous and early lymphatic tumor spread. Breast Cancer Research and Treatment, 2012, 131, 501-508.	2.5	15
41	Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer. Breast Cancer Research and Treatment, 2019, 174, 453-461.	2.5	15
42	Clinical Trials of Oncolytic Viruses in Breast Cancer. Frontiers in Oncology, 2021, 11, 803050.	2.8	13
43	Update Breast Cancer 2020 Part 3 â€œ Early Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2020, 80, 1105-1114.	1.8	12
44	EZH2 Loss Drives Resistance to Carboplatin and Paclitaxel in Serous Ovarian Cancers Expressing ATM. Molecular Cancer Research, 2020, 18, 278-286.	3.4	12
45	Update Breast Cancer 2020 Part 2 â€œ Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics. Geburtshilfe Und Frauenheilkunde, 2020, 80, 391-398.	1.8	12
46	Translational Highlights in Breast and Ovarian Cancer 2019 â€œ Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy. Geburtshilfe Und Frauenheilkunde, 2019, 79, 1309-1319.	1.8	11
47	Update Breast Cancer 2020 Part 4 â€œ Advanced Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2020, 80, 1115-1122.	1.8	11
48	Investigating the effects of additional truncating variants in DNA-repair genes on breast cancer risk in BRCA1-positive women. BMC Cancer, 2019, 19, 787.	2.6	10
49	Comparison of therapy benefit from standard anti-HER2 directed approaches in metastatic breast cancer (MBC) between initially HER2-positive patients and patients initially HER2-negative with switch to HER2-positive.. Journal of Clinical Oncology, 2021, 39, 1040-1040.	1.6	10
50	Update Breast Cancer 2021 Part 1 â€œ Prevention and Early Stages. Geburtshilfe Und Frauenheilkunde, 2021, 81, 526-538.	1.8	10
51	A Three-Dimensional Organoid Model of Primary Breast Cancer to Investigate the Effects of Oncolytic Virotherapy. Frontiers in Molecular Biosciences, 2022, 9, 826302.	3.5	10
52	Detection of disseminated tumor cells from the bone marrow of patients with early breast cancer is associated with high 21-gene recurrence score. Breast Cancer Research and Treatment, 2016, 156, 91-95.	2.5	9
53	Circulating miR-200 family as predictive markers during systemic therapy of metastatic breast cancer. Archives of Gynecology and Obstetrics, 2022, 306, 875-885.	1.7	9
54	Update Breast Cancer 2018 (Part 3) â€œ Genomics, Individualized Medicine and Immune Therapies â€œ in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2018, 78, 1110-1118.	1.8	8

#	ARTICLE	IF	CITATIONS
55	Simultaneous detection of circulating and disseminated tumor cells in primary breast cancer patients following neoadjuvant chemotherapy. Archives of Gynecology and Obstetrics, 2018, 297, 785-790.	1.7	6
56	Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients. International Journal of Cancer, 2019, 145, 2114-2121.	5.1	6
57	Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab. Cancers, 2020, 12, 3021.	3.7	6
58	Trastuzumab treatment of patients with early, HER2-positive breast cancer in 17 certified German breast cancer centers. Journal of Cancer Research and Clinical Oncology, 2022, 148, 719-726.	2.5	6
59	Update Breast Cancer 2020 Part 5 â€œ Moving Therapies From Advanced to Early Breast Cancer Patients. Geburtshilfe Und Frauenheilkunde, 2021, 81, 469-480.	1.8	6
60	Update Breast Cancer 2021 Part 2 â€œ Advanced Stages, Long-Term Consequences and Biomarkers. Geburtshilfe Und Frauenheilkunde, 2021, 81, 539-548.	1.8	6
61	The DETECT study concept: Individualized therapy of metastatic breast cancer.. Journal of Clinical Oncology, 2016, 34, TPS634-TPS634.	1.6	6
62	Measuring the Time to Deterioration for Health-Related Quality of Life in Patients With Metastatic Breast Cancer Using a Web-Based Monitoring Application: Longitudinal Cohort Study. JMIR Cancer, 2021, 7, e25776.	2.4	6
63	Implementation of an Electronic Patient-Reported Outcome App for Health-Related Quality of Life in Breast Cancer Patients: Evaluation and Acceptability Analysis in a Two-Center Prospective Trial. Journal of Medical Internet Research, 2022, 24, e16128.	4.3	6
64	Neoadjuvant Chemotherapy of Patients with Early Breast Cancer Is Associated with Increased Detection of Disseminated Tumor Cells in the Bone Marrow. Cancers, 2022, 14, 635.	3.7	6
65	Prediction of Non-sentinel Lymph Node Metastases After Positive Sentinel Lymph Nodes Using Nomograms. Anticancer Research, 2018, 38, 4047-4056.	1.1	5
66	Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study. BMC Cancer, 2019, 19, 611.	2.6	5
67	Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine. Geburtshilfe Und Frauenheilkunde, 2020, 80, 1134-1142.	1.8	4
68	Update Breast Cancer 2021 Part 3 â€œ Current Developments in the Treatment of Early Breast Cancer: Review and Assessment of Specialised Treatment Scenarios by an International Expert Panel. Geburtshilfe Und Frauenheilkunde, 2021, 81, 654-665.	1.8	4
69	Update Breast Cancer 2021 Part 4 â€œ Prevention and Early Stages. Geburtshilfe Und Frauenheilkunde, 2022, 82, 206-214.	1.8	4
70	How previous treatment changes the metabolomic profile in patients with metastatic breast cancer. Archives of Gynecology and Obstetrics, 2022, 306, 2115-2122.	1.7	4
71	Update Breast Cancer 2018 (Part 4) â€œ Genomics, Individualized Medicine and Immune Therapies â€œ in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2018, 78, 1119-1128.	1.8	3
72	Challenges and Opportunities for Real-World Evidence in Metastatic Luminal Breast Cancer. Breast Care, 2021, 16, 108-114.	1.4	3

#	ARTICLE	IF	CITATIONS
73	Germline BRCA1 and BRCA2 mutations in patients with HER2-negative metastatic breast cancer (mBC) treated with first-line chemotherapy: Data from the German PRAEGNANT registry.. Journal of Clinical Oncology, 2019, 37, 1048-1048.	1.6	3
74	A high-risk 70-gene signature is not associated with the detection of tumor cell dissemination to the bone marrow. Breast Cancer Research and Treatment, 2018, 169, 305-309.	2.5	2
75	Detection of disseminated tumor cells in bone marrow as an independent prognostic factor in primary ovarian cancer patients.. Journal of Clinical Oncology, 2012, 30, 5042-5042.	1.6	2
76	Detection and prevalence of disseminated tumor cells from the bone marrow of early stage male breast cancer patients. Breast Cancer Research and Treatment, 2015, 152, 51-55.	2.5	1
77	Heregulin (HRC) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany. BMC Cancer, 2020, 20, 1091.	2.6	1
78	The SOX2 Status of Disseminated Tumor Cells in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. Anticancer Research, 2021, 41, 2849-2858.	1.1	1
79	An Activity Tracker-Guided Physical Activity Program for Patients Undergoing Radiotherapy: Protocol for a Prospective Phase III Trial (OnkoFit I and II Trials). JMIR Research Protocols, 2021, 10, e28524.	1.0	1
80	C05- BRCA mutations are associated with higher CAG numbers found in various polyglutamine disorders. , 2018, , .		0
81	Abstract PS17-42: A fast and effective 3D preclinical assay system comprised of patient derived breast cancer microtumors combined with DigiWest protein signaling pathway analyses for therapeutic response prediction (Project PRIMO). , 2021, , .		0
82	Circulating tumor cells in metastatic breast cancer: Are they a strong and independent predictor of poor progression-free and overall survival?. Journal of Clinical Oncology, 2012, 30, 1090-1090.	1.6	0
83	Accuracy of MRI, mammography (MG), and 2D and 3D ultrasound (2DUS/3DUS) in determining the pathologic tumor response after neoadjuvant chemotherapy (NACT) in breast cancer patients.. Journal of Clinical Oncology, 2012, 30, 1067-1067.	1.6	0
84	Prognostic relevance of induced and spontaneous apoptosis of disseminated tumor cells in primary breast cancer patients.. Journal of Clinical Oncology, 2012, 30, e21003-e21003.	1.6	0
85	Disseminated tumor cells in bone marrow of patients with endometrial and cervical cancer.. Journal of Clinical Oncology, 2013, 31, 5598-5598.	1.6	0
86	The persistence of disseminated tumor cells after systemic therapy and their influence on prognosis in early breast cancer patients.. Journal of Clinical Oncology, 2013, 31, 1030-1030.	1.6	0
87	Prognostic impact of changes in circulating tumor cells (CTC) in metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2013, 31, 11012-11012.	1.6	0
88	Bisphosphonate treatment of primary breast cancer patients with disseminated tumor cells in the bone marrow.. Journal of Clinical Oncology, 2014, 32, 11044-11044.	1.6	0
89	The DETECT Study Program: Personalized treatment in advanced breast cancer based on circulating tumor cells (CTCs).. Journal of Clinical Oncology, 2015, 33, TPS11109-TPS11109.	1.6	0
90	Discordance between HER2-phenotype on circulating tumor cells and primary tumor in women with advanced breast cancer.. Journal of Clinical Oncology, 2015, 33, 11003-11003.	1.6	0

#	ARTICLE	IF	CITATIONS
91	RIBECCA: A phase IIIb, multicenter, open label study for women with estrogen receptor-positive locally advanced or metastatic breast cancer treated with ribociclib (LEE011) in combination with letrozoleâ€”Results of the second interim analysis.. Journal of Clinical Oncology, 2019, 37, 1061-1061.	1.6	0
92	Update Mammakarzinom 2021 Teil 1 â€” PrÃvention und frÃ¼he Krankheitsstadien. Senologie - Zeitschrift FÃ¼r Mammadiagnostik Und -therapie, 2021, 18, 377-390.	0.0	0